These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22668245)

  • 1. Antioxidants as antidepressants: fact or fiction?
    Scapagnini G; Davinelli S; Drago F; De Lorenzo A; Oriani G
    CNS Drugs; 2012 Jun; 26(6):477-90. PubMed ID: 22668245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative stress markers in affective disorders.
    Siwek M; Sowa-Kućma M; Dudek D; Styczeń K; Szewczyk B; Kotarska K; Misztakk P; Pilc A; Wolak M; Nowak G
    Pharmacol Rep; 2013; 65(6):1558-71. PubMed ID: 24553004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness.
    Maes M; Galecki P; Chang YS; Berk M
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Apr; 35(3):676-92. PubMed ID: 20471444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects.
    Lopresti AL; Hood SD; Drummond PD
    J Psychopharmacol; 2012 Dec; 26(12):1512-24. PubMed ID: 23035031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural products, micronutrients, and nutraceuticals for the treatment of depression: A short review.
    Nabavi SM; Daglia M; Braidy N; Nabavi SF
    Nutr Neurosci; 2017 Apr; 20(3):180-194. PubMed ID: 26613119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of oxidative stress in depressive disorders.
    Michel TM; Pülschen D; Thome J
    Curr Pharm Des; 2012; 18(36):5890-9. PubMed ID: 22681168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: results from a meta-analysis.
    Jiménez-Fernández S; Gurpegui M; Díaz-Atienza F; Pérez-Costillas L; Gerstenberg M; Correll CU
    J Clin Psychiatry; 2015 Dec; 76(12):1658-67. PubMed ID: 26579881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.
    Mokoena ML; Harvey BH; Viljoen F; Ellis SM; Brink CB
    Psychopharmacology (Berl); 2015 Aug; 232(16):2921-38. PubMed ID: 25877744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder.
    Behr GA; Moreira JC; Frey BN
    Oxid Med Cell Longev; 2012; 2012():609421. PubMed ID: 22693652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid prevents depressive-like behavior and hippocampal antioxidant imbalance induced by restraint stress in mice.
    Budni J; Zomkowski AD; Engel D; Santos DB; dos Santos AA; Moretti M; Valvassori SS; Ornell F; Quevedo J; Farina M; Rodrigues AL
    Exp Neurol; 2013 Feb; 240():112-21. PubMed ID: 23142187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and chronic treatment with quetiapine induces antidepressant-like behavior and exerts antioxidant effects in the rat brain.
    Ignácio ZM; Réus GZ; Abelaira HM; de Moura AB; de Souza TG; Matos D; Goldim MP; Mathias K; Garbossa L; Petronilho F; Quevedo J
    Metab Brain Dis; 2017 Aug; 32(4):1195-1208. PubMed ID: 28477202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events.
    Maciel AL; Abelaira HM; de Moura AB; de Souza TG; Rosa T; Matos D; Tuon T; Garbossa L; Strassi AP; Fileti ME; Goldim MP; Mathias K; Petronilho F; Quevedo J; Réus GZ
    Brain Res Bull; 2018 Mar; 137():204-216. PubMed ID: 29253605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurobiology of depression and mechanism of action of depression treatments.
    Blier P
    J Clin Psychiatry; 2016 Mar; 77(3):e319. PubMed ID: 27046319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.
    Maes M; Fišar Z; Medina M; Scapagnini G; Nowak G; Berk M
    Inflammopharmacology; 2012 Jun; 20(3):127-50. PubMed ID: 22271002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for major depressive disorder.
    Kennedy SH; Rizvi SJ
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):439-53. PubMed ID: 19637989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
    Yang C; Bosker FJ; Li J; Schoevers RA
    BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.
    Pitsillou E; Bresnehan SM; Kagarakis EA; Wijoyo SJ; Liang J; Hung A; Karagiannis TC
    Mol Biol Rep; 2020 Jan; 47(1):753-770. PubMed ID: 31612411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open questions in current models of antidepressant action.
    Tanti A; Belzung C
    Br J Pharmacol; 2010 Mar; 159(6):1187-200. PubMed ID: 20132212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
    Berk M; Dean OM; Cotton SM; Jeavons S; Tanious M; Kohlmann K; Hewitt K; Moss K; Allwang C; Schapkaitz I; Robbins J; Cobb H; Ng F; Dodd S; Bush AI; Malhi GS
    J Clin Psychiatry; 2014 Jun; 75(6):628-36. PubMed ID: 25004186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.